TARA (Protara Therapeutics) Pangali Forward P/E
Protara Therapeutics is developing a comprehensive environment to combat oncology and rare pathologies, creating unique approaches to the therapy of lymphatic disorders. This price chart demonstrates the Forward P/E, which currently stands at 0.00. The company is also testing targeted drugs against bladder cancer, leveraging its orphan drug developer status to minimize market pressure.
Ringkesan rincian data analitis Protara Tx (TARA)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Protara Therapeutics|TARA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Protara Therapeutics|TARA - Gunggung tanggungan utang perusahaan|Rasio utang marang kapitalisasi buku Protara Therapeutics Inc|TARA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Protara Therapeutics|Indikator likuiditas cepet protaratx.com
- rincian asil keuangan lan kelipatan valuasi:
TARA - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Protara Therapeutics|TARA - Pangali P/E|Rega marang bathi mangsa ngarep Protara|TARA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Protara Therapeutics Inc|TARA - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Protara Therapeutics|TARA - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan protaratx.com|TARA - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Protara Therapeutics
Pambiji fundamental perusahaan:TARA Protara Therapeutics, Inc.
Protara Therapeutics develops innovative drugs for the therapy of orphan oncological diseases. By analyzing the company's forward P/E ratio, an investor can see the relationship between the current quote and projected net income. This metric objectively measures market expectations regarding the monetization of scientific research and the costs of RSU packages for scientists. The indicator's trend allows for an assessment of the degree of business overvaluation. This tool is critically important for calculating the fundamental risks of a biopharmaceutical asset.
Pesaing langsung
Prakiraan rega marang bathi ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (RevMed)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Therapeutics (BCAX) - Rega marang bathi mangsa ngarep|Personalis Inc - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Corp DCTH|Rega marang bathi mangsa ngarep Y-mAbs Therapeutics (YMAB)|AURA: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep Candel Therapeutics, Inc. CADL|Pangali mangsa ngarep rega marang bathi ARAY|SLS - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Actuate Therapeutics Inc|CTOR (Citius Oncology, Inc.) - Prakiraan rega marang bathi|HURA: Rasio kapitalisasi marang bathi mangsa ngarep|FATE (Fate Therapeutics) - Pangali Forward P/E|Pangali Forward P/E Aadi Bio|Rega marang bathi mangsa ngarep TScan Therapeutics (TCRX)|CSBR (championsoncology.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E XBIT (XBiotech)|Pangali Forward P/E CEL-SCI Corp. CVM|OSTX: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Prakiraan rega marang bathi|ANL: Rasio kapitalisasi marang bathi mangsa ngarep|VERU (Veru Inc.) - Pangali Forward P/E|TPST: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E XLO|RENB - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Mural Oncology MURA|Pangali mangsa ngarep rega marang bathi KAPA|OnKure - Pangali Forward P/E|GDTC - Pangali Forward P/E|curis.com (CRIS) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake APLM (Apollomics)|THAR (Tharimmune Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Advanced Biomed Corp ADVB|Prakiraan rega marang bathi GNPX (Genprex, Inc.)|Pangali Forward P/E calidibio.com (CLDI)|Sunshine Biopharma, Inc. - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep XBIO (Xenetic Biosciences Inc.)|Salarius - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Kitov Pharma PPBT|AONC: Pangali Forward P/E|Prakiraan rega marang bathi beigene.com|Rega marang bathi mangsa ngarep Checkpoint Therapeutics, Inc.|elevationoncology.com (ELEV) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ICAD (iCAD, Inc.)|Rasio kapitalisasi marang bathi mangsa ngarep IKNA|Pangali Forward P/E NTBL (Notable Labs, Ltd.)|Pangali Forward P/E Viracta Therapeutics Inc. VIRX|MOR - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi NAYA (NAYA Biosciences Inc)|AAPGV: Pangali Forward P/E
